Even though there are more hurdles to overcome for developing clinically applicable HK2 inhibitors, there could be promising combination agents to enhance immunotherapy or chemotherapy responses by releasing immune cells from metabolic competition and directly decreasing tumor cell survival. The gene discussed is HK2; the disease is neoplasm.